TECHWIRE 30
(CIX: WRAL30)  1,095.48  down arrow-0.72  (-0.07 %)  Updated: 08:10 PM EDT, May 03 2016
(NQ: Apple)  95.18    (0 %)  Updated: 08:10 PM EDT, May 03 2016
(NY: Q)  67.46  down arrow-1.64  (-2.37 %)  Updated: 08:04 PM EDT, May 03 2016
(OP: BASFY)  78.54  down arrow-2.04  (-2.53 %)  Updated: 05:20 PM EDT, May 03 2016
(NQ: BCRX)  3.24    (0 %)  Updated: 08:10 PM EDT, May 03 2016
(NQ: BDSI)  2.99    (0 %)  Updated: 08:10 PM EDT, May 03 2016
(NQ: CEMP)  17.04    (0 %)  Updated: 08:10 PM EDT, May 03 2016
(NQ: Cisco)  26.86    (0 %)  Updated: 08:10 PM EDT, May 03 2016
(NQ: CREE)  23.57    (0 %)  Updated: 08:10 PM EDT, May 03 2016
(NQ: DARA)  0.88    (0 %)  Updated: 08:10 PM EST, Dec 04 2015
(NY: EMC)  26.16  down arrow-0.29  (-1.1 %)  Updated: 08:04 PM EDT, May 03 2016
(NQ: EXTR)  3.51    (0 %)  Updated: 08:10 PM EDT, May 03 2016
(NQ: Facebook)  117.43    (0 %)  Updated: 08:10 PM EDT, May 03 2016
(NY: GSK)  43.14  down arrow-0.15  (-0.35 %)  Updated: 08:04 PM EDT, May 03 2016
(NQ: Alphabet)  692.36    (0 %)  Updated: 08:10 PM EDT, May 03 2016
(NY: IBM)  144.13  down arrow-1.14  (-0.78 %)  Updated: 08:04 PM EDT, May 03 2016

Posts tagged “GSK”

Updated April 27

'Ecouraging start:' GSK sees rise in sales of vaccines, healthcare products

Pharmaceutical company GlaxoSmithKline says higher sales of vaccines and consumer healthcare products pushed up its earnings from core business by 19 percent in the first quarter. CEO Andrew Witty sees the results as an "encouraging start" for the year.

March 31

Premium Lock GSK moving to make more drugs available in poor countries

GSK   GSK said today it is taking steps to bring its medicines to more people living in the world's poorest countries.

Updated March 17

Premium Lock GSK CEO: Retirement not related to calls for giant's breakup

Andrew Witty  Drug giant GlaxoSmithKline made news official what had been rumored for months: CEO Andrew Witty is going to retire. Witty plans to step down a year from now. However, he says his decision is not linked to investor calls for breakup of the company.

March 17

Premium Lock GSK's CEO makes it official: He's retiring next year

Drug giant GlaxoSmithKline made news official what had been rumored for months: CEO Andrew Witty is going to retire. Witty plans to step down a year from now.

GSK's Andrew Witty on the ground in Africa GSK's Andrew Witty on the ground in Africa

Updated February 29

Premium Lock Reports: GSK begins search for successor to CEO Andrew Witty

Drug giant GlaxoSmithKline is preparing to launch what is called a "formal search" for a successor to Chief Executive Officer Andrew Witty, reports the prestigious Financial Times as well as the Reuters news service.

GSK's Andrew Witty on the ground in Africa GSK's Andrew Witty on the ground in Africa

February 22

Premium Lock GSK wraps up $1.46B HIV drug pipeline deal with Bristol-Myers Squibb

GSK's HQ in London             GlaxoSmithKline is boosting its own efforts to fight AIDS by closing on a deal to buy the HIV drug pipeline of Bristol-Myers Squibb . The transaction is worth as much as $1.46 billion. In May, GSK said it would invest $20 million in a deal with UNC-Chapel Hill to develop an AIDS cure.

Updated February 12

Premium Lock British government fines GSK $54M for delaying generic drugs

GSK in Zebulon  Britain's competition authority has fined drugmaker GlaxoSmithKline $54.5 million for stalling the potential entry of generic competitors of an anti-depressant drug Seroxat into the marketplace.

Updated February 3

Premium Lock GSK posts $616M loss for 4th quarter; CEO sees 'substantial progress'

GSK in Zebulon  British-based drugmaker GlaxoSmithKline (NYSE: GSK) posted a loss of $616 million for the fourth quarter of 2015 - compared with a profit of over $1 for the same period a year earlier- as the company moved to integrate new businesses. Its top exec says GSK is making progress.

February 2

Premium Lock GSK expands cancer drug development deal with Adaptimmune

Cancer research  GlaxoSmithKline, which sold its oncology portfolio to Novartis in 2014, is expanding a development deal with Adaptimmune to explore possible cancer treatments. GSK announces earnings on Wednesday.

February 2

Premium Lock GSK invests in another startup fund along with J&J

GSK's HQ in London             GlaxoSmithKline, which is under growing investor pressure to improve its financials, is investing alongside Johnson & Johnson in another startup fund. For the second time in a week, GSK moves to back new and emerging ventures in hopes of driving future growth.

Updated January 26

Premium Lock Sprint cutting jobs; Lenovo security bug; GSK investor pressure; Arista counter-sues Cisco

Bulldog In today's Bulldog wrapup of technology and life science news: Sprint is cutting jobs and closing six call centers; another security problem for Lenovo; investor pressure mounts for change at GSK; and Arista counter-sues Cisco.

Updated January 25

Premium Lock Lenovo adware suits; Google back taxes; GSK $15M in new fund; Novozymes poultry product

Bulldog In today's Bulldog wrapup of technology and life science news: Lenovo fights lawsuits over adware; Google pays back taxes in U.K.; GSK puts $15 million in new university drug development fund; and Novozymes launches a poultry product with French partner.

Updated January 21

Premium Lock Charlotte woman among 5 charged with scheme to steal GSK secrets

GSK in Zebulon  A woman who is a twin sister of a former scientists at GSK is charged conspiracy to steal secrets from the drug giant. The sister, who was fired recently by GSK, also is charged along with three others.

January 21

Premium Lock GSK, Pfizer, Merck join drug industry-government alliance to fight superbugs

Infections Drug giants GlaxoSmithKline, Pfizer and Merck, all of which have a big presence in North Carolina, are teaming with dozens of other companies and governments to form an alliance to fight "superbugs."

December 23, 2015

Premium Lock New GSK drug's price criticized; Google expands in Tennessee; 'Dotcom' faces extradition; Turing seeks CEO

Bulldog In today's Bulldog wrapup of technology and life science news: An independent group is criticizing the price of GSK's new asthma drug; Google to invfest $600 million in Tennessee data center expansion; Kim Dotcom faces extradition to the U.S.; and drug company Turing is looking for a new CEO to replace Martin Shkreli.

December 18, 2015

Premium Lock GSK buying HIV drug pipeline from Bristol-Myers Squibb in $1.46B deal

GSK's HQ in London             GlaxoSmithKline is boosting its own efforts to fight AIDS by agreeing to buy the HIV drug pipeline of Bristol-Myers Squibb in a deal valued at as much as $1.46 billion. In May, GSK said it would invest $20 million in a deal with UNC-Chapel Hill to develop an AIDS cure.

December 17, 2015

Premium Lock GSK arthritis drug advances; Washington sues tech support firm; streaming music fees go up; FDA OKs cheaper diabetes drug

Bulldog In today's Bulldog wrapup of technology and life science news: A new arthritis drug from GSK moves toward regulatory approval; the state of Washington is suing tech support firm iYogi, alleging it scams customers; streaming music fees are going up; and the FDA approves a cheaper diabetes drug.

December 3, 2015

Premium Lock GSK's $440M antibody deal; INC shareholders sell; Bioventus, PowerSecure make buys; Dara BioSciences merger advances

Bulldog In today's wrapup of technology and life science news: GSK strikes investment deal for antibodies; INC's big shareholders sell; Bioventus and PowerSecure make acquisitions; and Dara Biosciences moves ahead with merger.

Updated November 24, 2015

Premium Lock GSK inks $100 million deal with Idera Pharmaceuticals

GSK   GSK has struck a development agreement with Idera Pharmaceuticals, Inc., which develops drugs for patients with renal disease. The deal comes with an up-front payment of $2.5 million to Idera, and is worth as much as $100 million.

November 20, 2015

Premium Lock 1 in 3 two-year-olds in the United States have not received all recommended childhood vaccines, study finds

RTI International One-third of children did not receive all recommended vaccinations by 24 months of age. Western states had the lowest completion rates, Southern states had the highest.

Tags: Fiber, GSK, RTI
Techwire Inside Partners
The Skinny: A Blog by Rick Smith